Insider trading class actions are lawsuits brought on behalf of investors who bought or sold securities at prices they claim were artificially inflated or deflated because of material non-public information withheld by corporate insiders. In these cases, company executives, directors, or employees with access to confidential information trade stock before the information becomes public—allowing them to profit illegally while ordinary shareholders bear the losses. When the hidden information finally reaches the market, the stock price adjusts, and shareholders who traded during the period of deception suffer real financial harm. A class action consolidates these harmed investors into a single lawsuit for efficiency and leverage. The stakes are substantial.
In January 2026, New York’s Attorney General sued Emergent BioSolutions’ former CEO for allegedly selling over $10 million in company stock before publicly disclosed contamination issues crashed the price, ultimately settling for a $900,000 penalty and mandatory policy reforms. More recently, in April 2026, the CFTC brought the first-ever insider trading enforcement action in prediction markets, marking a significant expansion of how regulators police unfair trading. These cases represent just the visible tip—the SEC filed 456 enforcement actions in fiscal year 2025 alone, with total monetary relief exceeding $17.9 billion across all enforcement categories. For investors, understanding insider trading class actions is critical because they offer a path to recovery when executives or insiders betray shareholder trust. However, joining or initiating these cases requires careful timing, understanding settlement mechanics, and knowing what realistically can be recovered.
Table of Contents
- How Does an Insider Trading Class Action Work?
- The Current Wave of SEC and Regulatory Enforcement
- Real-World Example: The Emergent BioSolutions Case
- Insider Trading Class Actions vs. Other Securities Fraud Claims
- The Challenge of Proving Materiality and Timing
- The Emerging Frontier: Prediction Market Insider Trading
- Looking Forward: SEC Focus on Individual Accountability
- Conclusion
How Does an Insider Trading Class Action Work?
An insider trading class action begins when shareholders discover that an insider traded on material non-public information—usually when the company announces unexpected bad news, stock drops, and the timing of insider stock sales becomes suspicious. Attorneys then file a complaint in federal court claiming that insiders violated securities laws (typically Rule 10b-5, which prohibits trading while in possession of material non-public information) and that shareholders who traded during the deception period suffered injury. The class is defined narrowly: it includes only those who bought the stock between the date the insider started trading on the secret information and the date the information became public. This “class period” is crucial—shareholders who bought before the insider’s trades or after public disclosure have no claim. For example, in the Emergent BioSolutions case, the class period would span from when the CEO allegedly knew about contamination issues and began selling until Emergent publicly disclosed those problems.
Unlike other securities litigation, insider trading class actions don’t require proof of price inflation; they require proof that insiders possessed material information and traded while knowing it wasn’t public yet. Discovery and litigation can take years. Plaintiffs’ lawyers must obtain insider trading records, emails, and trading communications to prove the insider knew about material information. The defendant typically argues that the insider had independent reasons to sell, or that the information wasn’t truly material. If plaintiffs survive summary judgment, settlement negotiations often follow—with the defendant’s insurance carrier and counsel calculating exposure and a potential jury award.
The Current Wave of SEC and Regulatory Enforcement
The SEC dramatically intensified insider trading prosecution in 2025-2026, filing 456 enforcement actions with combined monetary relief reaching $17.9 billion. This includes significant cases targeting individual traders rather than just corporate entities—a strategic shift toward personal accountability. In one recent example, the SEC charged Eamma Safi and Zhi Ge for running an international insider trading ring that generated $17.5 million in illegal profits by trading on confidential information about pending corporate announcements. In another, former equity trading head Ryan Squillante allegedly traded on confidential information across more than 10 public companies, netting $217,000 in illegal gains—a seemingly smaller profit that still triggered federal charges and enforcement action.
These prosecutions signal a critical limitation: SEC enforcement and class action litigation are different paths. The SEC can fine individuals, ban them from securities roles, and refer cases to the Department of Justice for criminal prosecution. Class actions seek money for harmed shareholders from the defendant company or its insurance. A company settling an SEC case for fraud doesn’t automatically mean a class action settlement follows, though it often accelerates settlement negotiations because the company faces reputational damage and acknowledged violations. The biotech sector faces particular scrutiny, with regulators focusing on undisclosed risks, clinical trial failures, and contamination issues—precisely the type of situations that fuel insider trading accusations when executives sell before disclosure.
Real-World Example: The Emergent BioSolutions Case
In January 2026, New York Attorney General Letitia James sued Emergent BioSolutions’ former CEO for executing stock sales worth over $10 million before the company publicly acknowledged manufacturing contamination that threatened product reliability. The timing was damaging: the CEO sold substantial holdings while assuring investors (and the market) that operations were sound. When contamination issues came to light, the stock price fell, and shareholders who purchased during the deception period lost money. Emergent settled the enforcement case for $900,000 and agreed to amend its insider trading policies—a relatively modest penalty that reflects the challenge of proving what an executive actually knew and when.
However, this case also triggered shareholder lawsuits, with investors who bought during the undisclosed contamination period filing claims alleging securities fraud. The resolution illustrates a critical tradeoff: company executives often have plausible business reasons to sell stock (diversification, tax planning, personal expenses), making it difficult to prove they acted solely on non-public information. Prosecutors must connect trading patterns, timing, access to information, and circumstantial evidence to build a compelling case. Even when settlements occur, shareholder recoveries depend on settlement pool size, which is often constrained by insurance limits.
Insider Trading Class Actions vs. Other Securities Fraud Claims
Not all shareholder lawsuits are insider trading class actions. Many are securities fraud claims based on misleading statements, omissions, or disclosures—what lawyers call “10b-5 misrepresentation” cases. The difference matters. In a misrepresentation case, shareholders allege that the company issued false or misleading statements that inflated the stock price. Proof requires showing that the statement was false, material, and that reasonable investors relied on it. Insider trading, by contrast, focuses on unfair trading by people with access to secrets—the emphasis is on the insiders’ conduct, not necessarily on what the company said publicly.
This distinction affects case strength and recovery. Insider trading claims are narrower and harder to prove because they require evidence that insiders possessed specific material non-public information and traded on it. A class period is tightly defined by when the insider’s knowledge started and when disclosure occurred. In contrast, a misrepresentation case can cover a longer period if the company repeatedly issued false statements. A 2025 analysis found that 207 new securities lawsuits were filed in 2025—the lowest annual filing count in a decade outside of 2022—reflecting increased judicial skepticism and stricter pleading standards. Of those, insider trading claims represent a small subset, but they often pair with broader fraud allegations. Settlements in 2024 included 88 securities class actions with a median settlement of $14 million and total settlement value of $3.7 billion—numbers that dwarf individual insider trading recoveries alone.
The Challenge of Proving Materiality and Timing
One of the biggest obstacles in insider trading class actions is proving that the inside information was genuinely “material”—meaning it would have significantly influenced a reasonable investor’s decision. Courts interpret materiality strictly. A CEO’s knowledge that quarterly earnings will disappoint is clearly material. But knowledge that a minor regulatory review is underway, or that a product launch is being delayed by a few weeks, may not be. Prosecutors and plaintiffs’ lawyers must establish through expert testimony and discovery that the information in question was the kind that would shift a stock’s price when disclosed. Timing creates another hurdle.
An insider may sell stock for months or years before the hidden information becomes public. During that time, other news and market forces affect the stock price. When the bad news finally arrives, attributing the price decline solely to the previously hidden information becomes complex. A jury must believe that the specific information at issue caused the specific price movement—a causation challenge that defendants exploit aggressively. Additionally, if an insider sells gradually or in small increments, it may be harder to prove they were trading specifically on confidential information rather than executing a planned trading program. These evidentiary barriers mean that insider trading class actions, while theoretically powerful, often settle for less than the underlying harm because the proof burden is so high.
The Emerging Frontier: Prediction Market Insider Trading
On April 23, 2026, the CFTC brought the first-of-its-kind insider trading enforcement action against a prediction market trader, marking a significant expansion of insider trading law into new asset classes. Prediction markets allow people to bet on the outcomes of real-world events—elections, corporate earnings, product launches—with payouts based on event results. These markets have historically operated in legal gray areas, but the CFTC action confirms that traditional insider trading prohibitions now extend to them. If someone with access to material non-public information about an outcome trades prediction market contracts on that outcome, they’ve committed insider trading under federal law.
This development creates new litigation opportunities and risks. Shareholders of companies whose information was traded on in prediction markets may have novel class action claims. However, the nascent nature of prediction market regulation means that case law is developing in real time, settlement frameworks don’t yet exist, and courts haven’t clearly articulated damages standards. Investors considering participation in such litigation should understand that they are essentially pioneering claimants in an area without established precedent.
Looking Forward: SEC Focus on Individual Accountability
The SEC’s stated priorities going forward emphasize prosecution of individuals rather than corporate penalties alone, combined with sustained focus on biotech sector disclosures. This shift has practical implications for future insider trading class actions. Individual executives face personal liability, asset freezes, and reputational destruction—creating stronger incentives to settle shareholder claims quickly.
At the same time, stricter scrutiny of biotech insiders’ trading and disclosure practices means more cases will likely emerge from that sector, where information about clinical trials, FDA approvals, and manufacturing issues is highly sensitive and material. Looking ahead, expect more cases targeting smaller profit amounts (like the Ryan Squillante case generating $217,000) and more actions in emerging areas like prediction markets. The message from regulators is clear: insider trading enforcement is expanding, not contracting.
Conclusion
Insider trading class actions represent an important mechanism for shareholders to recover losses when executives and insiders betray their trust by trading on secrets. Recent cases—from the Emergent BioSolutions contamination scandal to the first prediction market insider trading prosecution—demonstrate that regulators are actively pursuing these violations and that shareholder lawsuits follow. However, these cases are complex, with high proof burdens around materiality, causation, and the timing of insider knowledge.
Settlements depend on strong evidence, insurance availability, and the willingness of defendants to avoid trial. If you believe you were harmed by insider trading, consult a securities attorney promptly. Class action participation requires meeting strict class period definitions, and the statute of limitations imposes tight deadlines. Given that the median insider trading class settlement reaches into the millions and that regulatory enforcement is accelerating, documenting your trades during suspected insider trading windows and understanding settlement mechanics is essential to protecting your rights.